Biotechnology | Pharmaceutical | Research and Science | Clinical Trials Print this Release Return to Headlines August 01, 2006 07:00 AM US Eastern Timezone The Immune Response Corporation Receives Approval for Expansion of Phase II Trial in France for Investigative HIV Immunotherapy IR103 BIOWIRE2K CARLSBAD, Calif.--(BUSINESS WIRE)--Aug. 1, 2006--The Immune Response Corporation (OTCBB:IMNR) announced today the receipt of approvals to expand its Phase II IR103 study in drug-naive HIV patients to include clinical sites in France. The trial, which is currently ongoing at several sites in Italy, will examine IR103, a second-generation immunotherapy, as a first-line treatment for drug-naive HIV-infected individuals not yet recommended for antiretroviral therapy according to current medical guidelines. Ultimately, more than 200 drug-naive patients will be enrolled in two parallel clinical studies being conducted in France and Italy, Canada and the UK.
